Zydus Lifesciences said the USFDA concluded its inspection of the company’s SEZ II manufacturing facility in Ahmedabad with one observation and no data integrity-related observations.

Zydus Lifesciences said the USFDA concluded its inspection of the company’s SEZ II manufacturing facility in Ahmedabad with one observation and no data integrity-related observations.

Zydus Lifesciences announced that the USFDA conducted an onsite inspection of the pharmacovigilance and post marketing surveillance system at the company's office in New Jersey, USA, from September 22 to September 25, 2026, which closed with NIL observations.

Zydus Lifesciences said on Monday, September 28, a US Food and Drug Administration inspection at its manufacturing facility at SEZ II, Ahmedabad, has concluded with one observation.

Zydus Lifesciences shares hit a 52-week high after its New Jersey USFDA inspection concluded with zero observations.

Zydus Lifesciences announced that a US Food and Drug Administration inspection of its pharmacovigilance and post-marketing surveillance system at its New Jersey office concluded with nil observations.

Zydus Lifesciences' New Jersey office received nil observations in its USFDA inspection for its pharmacovigilance and post-marketing surveillance system.